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An Overview of Common Findings and 
Observations About Pathogenic Mechanisms 
and Possible Prevention 
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Definition, Clinical Presentation and Suspected Etiology 
Very good to excellent one year patient and graft survival rates 
at most experienced transplant centers has shifted considerable at-
tention in research away from short term complications like acute 
rejection to chronic rejection (CR), which is the major obstacle to 
long-term, morbidity-free survival (reviewed in detaiF). In com-
parison to acute rejection, chronic rejection is a more indolent. but 
progressive form of allograft injury, which is largely irreversible 
and eventually results in allograft failure. 
Although the term "chronic" implies a temporally prolonged 
course, many cases of chronic rejection clearly evolve from severe 
or inadequately controlled acute rejection episodes because of non-
compliance or an inability to maintain immunosuppression, or to 
monitor the allograft for rejection. Such patients experience a pro-
gressive decline in organ function over a period of weeks to 
months. Another significant cohort of patients slowly develop 
graft dysfunction and eventual failure over a period of years from 
chronic rejection. This may be attributable to .. clinically silent" 
rejection episodes that go undetected or to other factors. A third 
cadre of patients become trapped in a disheartening cycle that 
alternates between rejection and infection (e.g .• CMY, polyoma 
virus"). in which the immunosuppressive therapy is repeatedly in-
creased then decreased. Each turn of the cycle further damages the 
organ. which eventually fails with features of chronic rejection. 
Three lines of evidence best support the contention that 
alloimmunity is the major etiologic factor. as originally sus-
pected_J ·• First, isografts rarely, if ever, suffer the same set of 
changes seen in allografts with chronic rejection. although some 
isografts do develop chronic arterial lesions. but they are delayed 
in onset and less severe in comparison [Q allografts.5-a Secondly, 
patients who are at high risk of severe or persistent acute rejec-
tion:9-1~ and those inadequately immunosuppressed have a higher 
rate of chronic rejection. 17.[8This is likely related to an increased 
risk of alloreactivity like that seen with donor/recipient racial or 
ethnic mismatches. [9-23 sex mismatching. [414 viral infections"5-32 
and in patients treated with immune activating drugs.33 Finally. 
greater MHC mismatching results in a higher rate of long term 
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allograft failure, although the data for liver allografts is 
conflicting. [9.20.22.23.34-39 
Common Histopathological Features 
There are several similar histopathologic and pathophysiologic 
manifestations of chronic rejection in the various solid organ al-
lografts which enables us to cover the topic from a common per-
spective. The common features include: a) patchy, organized inter-
stitial inflammation; b) patchy interstitial fibrosis and associated 
parenchymal atrophy; c) graft vascular disease (GVD) which pn':. 
marily manifests as fibrointimal hyperplasia of arteries; d) destruc-
tion of epithelial-lined conduits; and e) destruction and atrophy 
of organ-associated lymphoid tissue and lymphatics. Except for 
widespread GVD, which is rarely detected on biopsy and an un-
common finding in the absence of chronic rejection. none of these 
features. in isolation. is diagnostic for chronic rejection. Each can 
be seen with non-chronic rejection related complications. In faa. 
the usefulness of a biopsy in establishing the diagnosis of chronic 
rejection is directly related co the ability to sample the target 
structures. 
There are however, certain manifestations of chronic rejection 
that are accentuated in specific organs because of physioanatomic 
variations and interactions with the environment. For example. 
GVD is the primary manifestation of chronic rejection in heart 
allograftsK~P which may be related to the natural tendency of the 
heart to develop atherosclerosis. In lung transplantation, destruc-
tion of the small bronchioles is the major chronic rejection-related 
insult limiting long-term survival which could be related to bron-
chial exposure to environmental antigens/infection. [2.42,44--17 GVD 
is not a significant problem after lung transplantation. 12.42.-I+-46 In 
the liver. both bile duct loss and GVD (see below) togerh~r con-
tribute to allograft failure. 48-52 It is clear however that these 
physioanatomic and "environmental factors" clearly exert their 
influence in the context of severe and/or persistent alloreactivicy. 
a contention based on the experience with isografts mentioned 
above. 
In addition, there are majot differences in the incidence of 
chronic rejection 5 years after transplantation: it affects roughly 
25-50% of hearts; 50-60% isolated lungs, 40-60% pancreas 
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and 30% of kidney allografts. but only 7-20% of liver allografts 
(reviewed in greater detail in reference I). Thus. almough mere is 
no accepted generic histopamological definition of chronic rejec-
tion equally applicable to all organs. the common features can be 
used as a general guide for analysis and comparison. Each of these 
common features is discussed in more detail below. 
Patchy, Organized Interstitial Inflammation 
A mononuclear interstitial inflammatory infiltrate is a constant 
feature of chronic rejection. and architecturally organized nodu-
lar aggregates of lymphocytes and macrophages often arise from 
a background of isolated mononuclear cells scattered sparingly 
throughout me organ.1.53.54 Overall. me infiltrates consist prima-
rily of CD4+ and CD8+T cells and macrophagesY·60 In contrast 
to acute rejection, B cells and plasma cells are seen in greater num-
bers,55.56.61 while eosinophils are less frequently seen.62 
In all allografts, the organized nodular aggregates are often 
located near the adventitia of arteries wim GVD. near peripheral 
nerve trunks, and me serosa or capsule of organs.53.54.63 These are 
also me site of draining lymphatics. The overall arrangement and 
me occasional presence of germinal centers I .53.54 wimin mese nod-
ules is typical of organized lymphoid tissue in me regional lymph 
nodes, and is indicative of ongoing intra-organ antigen presenta-
tion. A similar process occurs in autoimmune diseases, such as 
Crohn's disease and Hashimoto's myroiditis.53.54 
The aggregates and cells individually scattered mroughout me 
interstitium are often seen in close association with damaged pa-
renchymal cells. Cytokine mRNA analysis and immunohis-
tochemical studies for effector molecules showing granzyme B and 
the presence ofThl-like cytokines IL-2 and IFN_y.(,o 
Patchy Interstitial Fibrosis and Associated Parenchymal 
Atrophy 
Over time, the necro-inflammatory activity discussed above. 
results in patchy interstitial fibrosis and atrophy of parenchymal 
cells. This process is accentuated in adventitia of arteries and in 
sites of ongoing immunological activity near epithelial-lined con-
duits (discussed in more detail below). The evolving fibrogenesis 
is likely related to ongoing parenchymal and microvasculature in-
jury (see below) associated wim me release of multiple growth 
fac[ors,6-1-68 which results in the deposition of tenascin and omer 
matrix components,69.70 endomelin71 and activation of interstitial 
myofibroblasts.7°The presence of larger scars is indirect evidence 
that ischemic injury with healed infarcts also contribute to 
fibrogenesis. 40 
Graft Vascular Disease 
Graft vascular disease (GVD) affects the majority of solid or-
gan allografts with chronic rejection to some degree and accounts 
for the most serious physiological consequences in heart. kidney, 
and pancreatic allografts. It is of secondary importance in some 
liver allografts because destrUction of the bile ducts is of more im-
portance and GVD is an uncommon problem for lung allografts. 
Nevermeless. GVD has become synonymous with chronic rejec-
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tion and has received me most research attention, even though 
mere are other well-known pathologic aspects of chronic rejection 
and in some allografts GVD is not a significant problem. 
Caveats aside, GVD manifests primarily as concentric arterial 
intimal mickening and adventitial fibrosis,40·41.72-74 but occasional 
mild venous involvementH.74.75 and focal destruction of me mi-
crovasculature (e.g. renal glomeruli and peri-biliary capillary 
plexus YS.76.n are also seen. GVD should be separated from athero-
sclerosis. which is endemic in the general population. but mere are 
overlapping characteristics that make distinction difficult in some 
cases. This is particularly trUe for organs such as the heart mat are 
norrna1Iy prone to amerosclerosis, but less of a problem in athero-
resistant organs, like me liver. 
In general. GVD more often involves botb me extra-organ (e.g., 
epicardial. hepatic hilar, etc.) and first and second-order branches 
of medium-sized intra-ocgan muscular arteriesK~OKTO-T4 in contrast 
to amerosclerosis, which primarily affects the extra-organ portion 
of the vessels. However. involvement of me intra-organ arterial tree 
by GVD is not as diffuse as one might expect ftom a review of the 
pathology literature~OKTO-T4 and me lesions often begin and evolve 
more quickly near branch points.40 
Except for me kidney, arteries commonly affected by GVD are 
rarely sampled in allograft biopsies routinely used to monitor for 
rejection. Thus, reconstruction of events preceding me develop-
ment of GVD depends on examination of many failed allograft: 
and autopsy specimens obtained at serial time points after trans-
plantation. An early phase of GVD with which most investigators 
are familiar is inflammatory arteritis showing intimal inflamma-
tion and/or antibody deposition. This is a histopathological 
marker of severe acute rejection in all allografts and results in 
endomelial damage, loss of barrier function and the influx of dot-
ting proteins (including fibrin), platelets, blood cells and lip-
ids,6s.78-110 all of which disrupt intimal homeostasis and trigger a 
macrophage influx. The media often shows edema and individual 
myocyte apoptosis. The adventitia is usually edematous and often 
contains a cuff of lymphocytes and macrophages. The intimal 
injury leads to a stereotypic repair response that results in 
fibroinrimal hyperplasia and eventual lumenal narrowing.64•74.ll 1-86 
Intimal inflammation is not observed in milder grades of acute 
rejection. yet some of mese patients go on to develop chronic re-
jection. Instead, me inflammation is often limited to me adventi-
tia. Even so. adventitial inflammation or injury alone can trigger 
an arterial repair response culminating in fibrointimal hyperpla-
sia.s4.8MI Thus, GVD may not require intimal inflammation or 
direct endothelial injury ftom antibodies or cells. 
The preferential localization of leukocytes in me adventitia and 
intima of arteries suggests that these are me most important an-
tigenic targets or sites of arterial damage;40·73.83.n-9s That the 
endomelium is targeted in some reactions is not particularly sur-
prising, since it is well-known to be immunologically active. The 
adventitia contains a lymphatic plexus which is surrounded by do-
nor dendritic cells making it a site ofboch peripheral sensitization 
in acute rejection and a conduit for emigrating leuko-
cytes,'I0.54.83.91.93.9S It is easy to envisage mat the shoulder region of 
a pre-existing donor atherosclerotic lesion would also be highly 
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immunogenic because of the presence of donor hematolymphoid 
cells and neovascularization. 
As GYD progresses. the intimal and/ or adventitial inflamma-
tion often persist, but the inflammatory cells migrate to the deeper 
aspects of the thickened intima where they are separated from an 
intact endothelial layer by a concentric ring of intimal 
myofibroblasts. Overall. the developing lesion vaguely resembles 
the shoulder region of an atherosclerotic plaque. discussed above. 
The deep intimal focus of inflammatory cells often communicates 
with an adventitial sheath of lymphocytes and macrophages 
through a focally disrupted media. Thus. from a morphological 
perspective. the endothelia no longer appears to be the focus of 
immunologic activity. 
Immunophenotypic analyses have shown that the arterial in-
flammation consists primarily of an admixture of CD4 + and 
CD8+T cells. some of which show perf orin positivity and mac-
rophages. with occasional dendritic cells (marker of ongoing an-
tigenic presentation). eosinophils and plasma cells.40·62.83.92.96.98 
Mitotic activity within this popularion occurs at the same time as 
smooth muscle DNA synthesis. suggesting that the immunologi-
cal reactions and vessel repair are related. 1.40 In the final stages of 
GYD. the media of involved arteries becomes thinned and both 
the intima and the adventitia thickened. fibrotic and hypocellular. 
Focal destruction of the microvasculature of allografts is also 
part of GYD.48.66.76.77This process is probably related to direct 
immunological damage to the immunogenic microvascular 
endothelium and is best observed in renal and liver allografts. The 
glomerular characteristically evolve through a sequence of changes 
that eventually result in global glomerulosclerosis.77 In the liver. 
similar changes are seen in the peri-biliary plexus.48.76 which shares 
some morphological and functional similarities with the renal 
glomerulus. 
Destruction of Epithelial-lined Conduits 
Epithelial cells that line conduits used for exchange of sub-
stances with the environment. such as bronchioles. bile ducts, pan-
creatic ducts. renal tubular epithelium are particularly prone to 
damage during chronic rejection. There are several possible non-
exclusionary explanations for this observation: 1) the presence of 
a basement membrane. which could potentially playa role in mi-
gration. positioning and co-stimulation ofT-cells;99 2) an immu-
nologically active antigenic profile that is significantly different 
than other parenchymal cells. including class I and II MHC. and 
various adhesion and co-stimulatory molecules;·J9·loo and 3) the 
presence of nearby antigen presenting cells and lymphatics that 
facilitate the functional role of these conduits in processing envi-
ronmental antigen for local presentation and traffic to the regional 
lymph nodes. 
The bronchioles31.loo and bile ductsI8.48.so.5z.IOI.Ill6 are good ex-
amples of the last possible explanation for "targeting" of epithe-
lial conduits. A bronchiocentric or ductuloccntric immune re-
sponse precipitated by environmental or aucoantigens in an al-
lograft. creates inflammatory microenvironment that has the po-
tential co trigger a rejection reaction. Either reaction can compro-
mise the strucrural integrity of the conduit, and focally destroy the 
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local microvasculature and lymphatic drainage, which in turn can 
ischemically damage the conduit inhibit efficient antigen clearing. 
One could easily appreciate how this could lead to a vicious cycle. 
alternating berween a persistent and inadequate response to envi-
ronmental antigens/infections and allogeneic injury. resulting in 
a downward spiral of allograft structural integrity and function. 
In liver and lung allografts. an additional consideration is the ex-
clusive blood supply by the hepatic and bronchial arteries. respec-
tively. Either destruction of these vessels, or failure to revascularize 
them. can significantly conttibute to conduit injury.48.49.I07 
Destruction and Atrophy of Organ-associated Lymphoid Tissue 
All organs contains a nerwork of hematolymphoid cells that 
travel into and out of. and transiently occupy. the interstitium of 
all vascularized organs. These cells consist of mature T and B lym-
phocytes. macrophages, hematopoietic stem cells and dendritic 
cells. primarily derived from progenitors that migrate 
hematogenously trom the bone marrow. although maturation from 
local precursors can also contribute to this pool. In concert. they 
monitor the microenvironment and communicate with regional 
lymph nodes via the circulation and lymphatics. When the organ 
becomes an allograft. these cells are called "passenger leukocytes" 
and they are primarily responsible for triggering acute rejection 
reactions via the ability of mature dendritic cells co directly stimu-
late allogeneic T cells. 
Organs such as the lungs and intestines have a large specializeCi 
compartment of organ or mucosal-associated lymphoid tissue 
(MALT), commensurate with their task of directly dealing with 
antigens trom the external environment. In contrast. the liver is 
richly endowed with a large macrophage population. consistent 
with its role as a filter of various opsonized material and other 
physiological debris. Although not as extensive or well known, the 
kidney,l08 heart l ()9.11O and pancreas also have considerable intn-
organ immune networks. 
It is our opinion. that the significance and eventual functional 
re-establishment of this network has not received enough attention 
in either acute or chronic rejection. or tolerance induction. In gen-
eral. the therapeutic window for avoiding graft failure from rejec-
cion and infection from over-immunosuppression is most narrow 
for those organ with the largest component of mature T cells. such 
as the intestines and lungs. As soon as an allograft is revascularized. 
recipient immune cells circulate through the organ. including the 
organ-associated lymphoid tissues (GALT. BALT. portal lymphoid 
tissuey 1 1.115 and regional d.onor lymph nodes transplanted en bloc. 
with the organ. I 16 Donor cells also leave the allograft and lodge in 
recipient lymphoid tissues. I 17.1 18 Subsequently a bi-directional .. in 
vivo mixed lymphocyre response" occurs in the recipient lymphoid 
tissue and in the allograft: which manifests as acute rejec-
tion. III .[14.116The greater component of immunogenic cells, the 
more robust the initial reaction. 
Transplantation of an organ also transiently disrupts the effer-
ent lymphatics resulting in organ edema. which contributes to the 
re-implantation response. The lymphatic channels reconnect 
within rwo to three weeks. [19.IZO unless disrupted by acute rejection. 
which increases production of lymph fluid and again disrupts the 
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lymphatic microvasculature. Both of these insults contribute to the 
reappearance of graft edema and swelling during acute rejection 
reactions.119.121.124 
If immunosuppression is kept high during the early post-trans-
plant period. there is a gradual replacement of donor 
hematolymphoid cells or immune network with similar recipient 
cells and the intra-organ network. MALT and regional lymph node 
architecture is restored. 115 However. if the framework is disrupted 
during acute rejection. repopulation is prevented and the allografts 
develop chronic rejection. I IS In chronic rejection. the lungI24.125 and 
intestine 1l4 mucosal-associated lymphoid tissue and regional 
lymph nodes are often destroyed or undergo atrophy. Patchy inter-
stitial fibrosis also focally disrupts intra-organ lymphatics.54.l26 
Both of these changes undoubtedly contribute to an inability of 
chronically rejecting allografts to adequately process infectious 
agents and antigens that are normally cleared via these path-
ways.17.2803l.I25.127.129 In fact. it is tempting to speculate that failure 
to physiologically re-establish these systems after transplantation 
accounts for the frequent association between infection and 
chronic rejection. Conversely. one wonders whether this intra-or-
gan immune network also plays a role in maintaining tolerance to 
the organ.54.l:l(}.!32 
Lastly. disruption of lymphatic drainage. which can occur in 
the adventitia of arteries can produce arterial injury and intimal 
thickening similar to that seen with GVD. 133 Thus. weS4 and oth-
ers before us126 have suggested that this potential mechanism of ar-
terial injury might importantly contribute to the development of 
OA. 
The "Special Case" of Liver Allografts 
There are two fascinating aspects of chronic liver allograft 
rejection: its potential reversibility possibly related to ductal regen-
eration and liver progenitor cellsI.So.I34 and an appreciably lower 
incidence than other allografts. 1.13S Also pertinent is the observa-
tion that a liver allograft can also protect other organs ftom the 
same donor from chronic rejection.s4 
Theories explaining the special immunological properties of 
a liver allograft can be broadly separated into two general catego-
ries based on whether emphasis is placed on the parenchymal or 
non-parenchymal ftaction. Release of soluble donor MHC class 
I antigen from the allograft is cited as evidence supporting the 
importance of the parenchyma. 136 However. murine liver allografts 
are routinely accepted between strains of mice that show no dif-
ference between the class I loci but are mismatched for class IIl37 
and fully allogeneic liver allografts from class I or IT MHC defi-
cient mice. which do not shed soluble MHC antigens.IJ7.138 are also 
accepted. Other organs also secrete soluble MHC antigens 139 but 
they are routinely rejected. Finally. studies attempting to induce 
graft acceptance with administration of soluble donor 1vIHC have 
met with limited success. 
Another potential explanation for the importance of the pa-
renchyma relies on the concept that allogeneic hepatocyres provide 
only one of two signals needed for allogeneic lymphocyte activa-
tion. 14O which in turn. could theoretically result in the induction of 
anergy in the responding lymphocyre populations.14O Alternatively. 
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loss of passenger leukocytes ftom the allograft or graft adaptation 
could result in ignorance of the allograft. IH.W Such a pathway 
might be especially true for the liver. which is a sink for effete and 
highly activated cytotoxic T cells.14J.I44 
Our focus has been on the donor hematolymphoid cells within 
the liver. which might initially mediate activation induced clonal 
purging or deletion 145·151 which is followed by long term 
hematolymphoid microchimerismI47.152.153 sustained by donor he-
matopoietic stem contained within the liver,tS4-156 An important 
aspect of both of these mechanisms is that hematolymphoid cells 
are capable of pocent stimulation and have direct access to the 
recipient lymphoid tissue. However. it is difficult to understand 
how the initial purging would provide long term protection since 
one must account for perpetuation of non-reactivity. Freedom 
from chronic rejection requires long term unresponsiveness. An at-
tractive explanation might combine the initial clonal purging. fol-
lowed by "ignorance" of the allograft because of the adaptation 
and replacement of the passenger leukocytes. The situation could 
be likened to the expression of alloantigens on parenchymal cells 
in transgenic mice. Unfortunately. this ignorance can be disrupted 
by vital infections and other local immune activating 
events.142.157.1S8 which are difficult. if not impossible to avoid in an 
allograft. 
From our perspective. the immunologic mechanisms involved 
in perpetual graft acceptance and freedom from chronic rejection 
appear to be active and are probably not different from those re-
quired for self_tolerance.S4.1S9.16Z In essence. to permanently avoid 
chronic rejection. tolerance to the organ must be induced. and this 
requires transplantation and fUnctioning of the donor immune 
system.I60.161 
Summary 
In summary. there are histopathological features of chronic 
rejection that are common to all solid organ allografts. and immu-
nological injury seems to playa primary role in the initiation and 
progression of lesions. However. the final phenotypic expression 
of chronic rejection is dependent on an interaction between im-
munologic and physiologic/ environmental factors that results in 
one or another of these features predominating in certain organs. 
Finally. in addition to traditional clinical studies and experimen-
tal models. it will be important to study conditions of resistance 
to chronic rejection in an effort to prevent or avoid this disorder. 
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